查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771740

肝病藥物市場規模、佔有率、趨勢分析報告：產品、疾病、地區、細分市場預測，2025-2033

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝病藥物市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2033年，全球肝病藥物市場規模將達到402.9億美元，2025年至2033年的複合年成長率為7.9%。主要促進因素包括肝細胞癌等肝病發生率的上升，以及此類疾病患者巨大的未開發需求。此外，全球老齡人口的成長預計將推動未來市場需求的成長。

生物技術和製藥行業在研發上的巨額投入以及強大的產品線預計將成為未來一段時間推動肝病藥物市場成長的關鍵因素。各國政府和各大公司推出的疫苗接種計劃提高了人們對肝病及其預防的認知，從而促進了市場的成長。

市場根據產品和地區分類為兩個部分。新產品的快速推出推動了市場的成長。市場成長的動力源自於主要企業之間的策略聯盟和合資企業，以及新興國家日益增強的醫療保健意識。

肝病藥物市場報告重點

  • 由於全球慢性病毒性肝炎盛行率高、乙肝治療時間長、C肝 DAA 價格昂貴，抗病毒藥物將在 2024 年佔據市場主導地位，收入佔有率最大，為 39.84%。
  • 肝炎領域佔據市場主導地位，2024 年的收入佔有率最大，為 40.44%。由於慢性肝炎的普遍負擔和抗病毒治療的臨床成功，肝炎領域繼續成為主要的市場驅動力。
  • 北美佔據肝病藥物市場的最大佔有率，佔2024年全球收益的39.87%，受到肝病盛行率上升、人口老化和創新治療方法的推動。
  • 由於乙肝和丙肝盛行率高、非酒精性脂肪肝 (NAFLD) 患者數量增加以及醫療保健基礎設施不斷改善，預計亞太地區肝病藥物市場成長最快，預測期內複合年成長率為 9.19%。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章肝病藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章肝病藥物市場：產品業務分析

  • 2025年及2033年的產品市場佔有率
  • 產品細分儀表板
  • 2021-2033 年市場規模及預測、產品趨勢分析
  • 抗病毒藥物
  • 疫苗
  • 化療
  • 標靶治療
  • 免疫抑制劑
  • 免疫球蛋白
  • 皮質類固醇
  • 其他

第5章肝病藥物市場：疾病業務分析

  • 2025年及2033年疾病市場佔有率
  • 疾病細分儀表板
  • 2021-2033 年市場規模與預測、特定疾病趨勢分析
  • 肝炎
  • 自體免疫疾病
  • 非酒精性脂肪肝（NAFLD）
  • 癌症
  • 遺傳性疾病
  • 其他

第6章肝病藥物市場：區域、估計與趨勢分析

  • 2025年及2033年區域市場佔有率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • GSK plc
Product Code: 978-1-68038-540-3

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market size is expected to be valued at USD 40.29 billion by 2033, registering a CAGR of 7.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market with the largest revenue share of 39.84% in 2024 due to the high global prevalence of chronic viral hepatitis, long treatment durations for HBV, and premium pricing for HCV DAAs.
  • The hepatitis segment dominated the market with the largest revenue share of 40.44% in 2024, attributed to the widespread burden of chronic hepatitis and the clinical success of antiviral treatments, the hepatitis segment remains a major market driver.
  • North America held the largest share of the liver disease therapeutics market in 2024, accounting for 39.87% of global revenue, driven by the rising prevalence of liver disease, aging populations, and breakthrough therapies.
  • The liver disease therapeutics market in Asia Pacific is projected to grow at the fastest CAGR of 9.19% over the forecast period, fueled by the high prevalence of hepatitis B and C, rising NAFLD cases, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Liver Disease Therapeutics Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Antiviral Drugs
    • 4.4.1. Antiviral Drugs Market, 2021 - 2033 (USD Million)
  • 4.5. Vaccines
    • 4.5.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 4.8. Immunosuppressants
    • 4.8.1. Immunosuppressants Market, 2021 - 2033 (USD Million)
  • 4.9. Immunoglobulins
    • 4.9.1. Immunoglobulins Market, 2021 - 2033 (USD Million)
  • 4.10. Corticosteroids
    • 4.10.1. Corticosteroids Market, 2021 - 2033 (USD Million)
  • 4.11. Other Products
    • 4.11.1. Other Products Market, 2021 - 2033 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Hepatitis
    • 5.4.1. Hepatitis Market, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
  • 5.6. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.6.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market, 2021 - 2033 (USD Million)
  • 5.7. Cancer
    • 5.7.1. Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Genetic Disorders
    • 5.8.1. Genetic Disorders Market, 2021 - 2033 (USD Million)
  • 5.9. Other Diseases
    • 5.9.1. Other Diseases Market, 2021 - 2033 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Gilead Sciences, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AbbVie Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. F. Hoffmann-La Roche Ltd
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Takeda Pharmaceutical Company Limited.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck & Co., Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Novartis AG
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Pfizer Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. GSK plc
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global liver disease therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 5. Global liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 6. North America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 8. North America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 9. U.S. liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 10. U.S. liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 11. Canada liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 12. Canada liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 13. Mexico liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 14. Mexico liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 15. Europe liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 17. Europe liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 18. UK liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 19. UK liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 20. Germany liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 21. Germany liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 22. France liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 23. France liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 24. Italy liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 25. Italy liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 26. Spain liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 27. Spain liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 28. Norway liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 29. Norway liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 30. Denmark liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 31. Denmark liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 32. Sweden liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 33. Sweden liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 37. Japan liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 38. Japan liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 39. China liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 40. China liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 41. India liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 42. India liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 43. Australia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 44. Australia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 45. South Korea liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 46. South Korea liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 47. Thailand liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 48. Thailand liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 49. Latin America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 51. Latin America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 52. Brazil liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 53. Brazil liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 54. Argentina liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 55. Argentina liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 59. South Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 60. South Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 63. UAE liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 64. UAE liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 65. Kuwait liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 66. Kuwait liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Liver disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Liver disease therapeutics market dynamics
  • Fig. 12 Liver disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Liver disease therapeutics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Antiviral drugs market, 2021 - 2033 (USD Million)
  • Fig. 16 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 17 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Immunosuppressants market, 2021 - 2033 (USD Million)
  • Fig. 20 Immunoglobulins market, 2021 - 2033 (USD Million)
  • Fig. 21 Corticosteroids market, 2021 - 2033 (USD Million)
  • Fig. 22 Other products market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease market, 2021 - 2033 (USD Million)
  • Fig. 24 Hepatitis market, 2021 - 2033 (USD Million)
  • Fig. 25 Autoimmune diseases market, 2021 - 2033 (USD Million)
  • Fig. 26 Non-alcoholic Fatty Liver Disease (NAFLD) market, 2021 - 2033 (USD Million)
  • Fig. 27 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 28 Genetic disorders market, 2021 - 2033 (USD Million)
  • Fig. 29 Other diseases market, 2021 - 2033 (USD Million)
  • Fig. 30 Liver disease therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Europe liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 Latin America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 MEA liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework